mouse breast cancer cell line emt6 Search Results


paper n a sk br 3 atcc cat  (ATCC)
99
ATCC paper n a sk br 3 atcc cat
Paper N A Sk Br 3 Atcc Cat, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/paper n a sk br 3 atcc cat/product/ATCC
Average 99 stars, based on 1 article reviews
paper n a sk br 3 atcc cat - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
cvcl 7256 emt6 atcc  (ATCC)
94
ATCC cvcl 7256 emt6 atcc
Cvcl 7256 Emt6 Atcc, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cvcl 7256 emt6 atcc/product/ATCC
Average 94 stars, based on 1 article reviews
cvcl 7256 emt6 atcc - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
crl 3461  (ATCC)
98
ATCC crl 3461
Crl 3461, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/crl 3461/product/ATCC
Average 98 stars, based on 1 article reviews
crl 3461 - by Bioz Stars, 2026-03
98/100 stars
  Buy from Supplier
emt6 mouse triple-negative breast tumor cells  (Charles River Laboratories)
90
Charles River Laboratories emt6 mouse triple-negative breast tumor cells
(A and B) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing 4T1 mouse triple-negative breast tumor cells. (A) Scheme of treatments. (B) Overall survival data for the four groups of mice with different treatments (n = 8 or 10). (C and D) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing <t>EMT6</t> mouse triple-negative breast tumor cells. (C) Growth of primary tumors. Data are presented as mean ± SEM (n = 8 or 9). (D) Overall survival data for the four groups of mice with different treatments (n = 8 or 9). (E) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing LLC mouse lung cancer cells (n = 8–10). (F) Fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing Pan02 mouse pancreatic cancer cells (n = 7 or 8). (G) NP-G2–044 with anti-PD-1 and anti-CTLA-4 antibodies increase the overall survival of mice bearing PNEC30 mouse prostate cancer cells (n = 8 or 9).
Emt6 Mouse Triple Negative Breast Tumor Cells, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/emt6 mouse triple-negative breast tumor cells/product/Charles River Laboratories
Average 90 stars, based on 1 article reviews
emt6 mouse triple-negative breast tumor cells - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
mouse mammary adenocarcinoma cells emt6  (China Center for Type Culture Collection)
90
China Center for Type Culture Collection mouse mammary adenocarcinoma cells emt6
(A and B) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing 4T1 mouse triple-negative breast tumor cells. (A) Scheme of treatments. (B) Overall survival data for the four groups of mice with different treatments (n = 8 or 10). (C and D) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing <t>EMT6</t> mouse triple-negative breast tumor cells. (C) Growth of primary tumors. Data are presented as mean ± SEM (n = 8 or 9). (D) Overall survival data for the four groups of mice with different treatments (n = 8 or 9). (E) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing LLC mouse lung cancer cells (n = 8–10). (F) Fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing Pan02 mouse pancreatic cancer cells (n = 7 or 8). (G) NP-G2–044 with anti-PD-1 and anti-CTLA-4 antibodies increase the overall survival of mice bearing PNEC30 mouse prostate cancer cells (n = 8 or 9).
Mouse Mammary Adenocarcinoma Cells Emt6, supplied by China Center for Type Culture Collection, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse mammary adenocarcinoma cells emt6/product/China Center for Type Culture Collection
Average 90 stars, based on 1 article reviews
mouse mammary adenocarcinoma cells emt6 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
emt6/ar1 tumour-bearing balb/c mice  (Japan SLC inc)
90
Japan SLC inc emt6/ar1 tumour-bearing balb/c mice
(A and B) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing 4T1 mouse triple-negative breast tumor cells. (A) Scheme of treatments. (B) Overall survival data for the four groups of mice with different treatments (n = 8 or 10). (C and D) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing <t>EMT6</t> mouse triple-negative breast tumor cells. (C) Growth of primary tumors. Data are presented as mean ± SEM (n = 8 or 9). (D) Overall survival data for the four groups of mice with different treatments (n = 8 or 9). (E) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing LLC mouse lung cancer cells (n = 8–10). (F) Fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing Pan02 mouse pancreatic cancer cells (n = 7 or 8). (G) NP-G2–044 with anti-PD-1 and anti-CTLA-4 antibodies increase the overall survival of mice bearing PNEC30 mouse prostate cancer cells (n = 8 or 9).
Emt6/Ar1 Tumour Bearing Balb/C Mice, supplied by Japan SLC inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/emt6/ar1 tumour-bearing balb/c mice/product/Japan SLC inc
Average 90 stars, based on 1 article reviews
emt6/ar1 tumour-bearing balb/c mice - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
mouse cell line type strain origin emt 6 breast carcinoma balb c atcc ll 2  (ATCC)
99
ATCC mouse cell line type strain origin emt 6 breast carcinoma balb c atcc ll 2
(A and B) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing 4T1 mouse triple-negative breast tumor cells. (A) Scheme of treatments. (B) Overall survival data for the four groups of mice with different treatments (n = 8 or 10). (C and D) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing <t>EMT6</t> mouse triple-negative breast tumor cells. (C) Growth of primary tumors. Data are presented as mean ± SEM (n = 8 or 9). (D) Overall survival data for the four groups of mice with different treatments (n = 8 or 9). (E) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing LLC mouse lung cancer cells (n = 8–10). (F) Fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing Pan02 mouse pancreatic cancer cells (n = 7 or 8). (G) NP-G2–044 with anti-PD-1 and anti-CTLA-4 antibodies increase the overall survival of mice bearing PNEC30 mouse prostate cancer cells (n = 8 or 9).
Mouse Cell Line Type Strain Origin Emt 6 Breast Carcinoma Balb C Atcc Ll 2, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse cell line type strain origin emt 6 breast carcinoma balb c atcc ll 2/product/ATCC
Average 99 stars, based on 1 article reviews
mouse cell line type strain origin emt 6 breast carcinoma balb c atcc ll 2 - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
drug-resistant mouse mammary tumour (emt6/ar1) cells  (KAC Co Ltd)
90
KAC Co Ltd drug-resistant mouse mammary tumour (emt6/ar1) cells
(A and B) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing 4T1 mouse triple-negative breast tumor cells. (A) Scheme of treatments. (B) Overall survival data for the four groups of mice with different treatments (n = 8 or 10). (C and D) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing <t>EMT6</t> mouse triple-negative breast tumor cells. (C) Growth of primary tumors. Data are presented as mean ± SEM (n = 8 or 9). (D) Overall survival data for the four groups of mice with different treatments (n = 8 or 9). (E) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing LLC mouse lung cancer cells (n = 8–10). (F) Fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing Pan02 mouse pancreatic cancer cells (n = 7 or 8). (G) NP-G2–044 with anti-PD-1 and anti-CTLA-4 antibodies increase the overall survival of mice bearing PNEC30 mouse prostate cancer cells (n = 8 or 9).
Drug Resistant Mouse Mammary Tumour (Emt6/Ar1) Cells, supplied by KAC Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/drug-resistant mouse mammary tumour (emt6/ar1) cells/product/KAC Co Ltd
Average 90 stars, based on 1 article reviews
drug-resistant mouse mammary tumour (emt6/ar1) cells - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
emt-6 tumor-bearing mice  (GemPharmatech Co Ltd)
90
GemPharmatech Co Ltd emt-6 tumor-bearing mice
(A and B) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing 4T1 mouse triple-negative breast tumor cells. (A) Scheme of treatments. (B) Overall survival data for the four groups of mice with different treatments (n = 8 or 10). (C and D) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing <t>EMT6</t> mouse triple-negative breast tumor cells. (C) Growth of primary tumors. Data are presented as mean ± SEM (n = 8 or 9). (D) Overall survival data for the four groups of mice with different treatments (n = 8 or 9). (E) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing LLC mouse lung cancer cells (n = 8–10). (F) Fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing Pan02 mouse pancreatic cancer cells (n = 7 or 8). (G) NP-G2–044 with anti-PD-1 and anti-CTLA-4 antibodies increase the overall survival of mice bearing PNEC30 mouse prostate cancer cells (n = 8 or 9).
Emt 6 Tumor Bearing Mice, supplied by GemPharmatech Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/emt-6 tumor-bearing mice/product/GemPharmatech Co Ltd
Average 90 stars, based on 1 article reviews
emt-6 tumor-bearing mice - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
crl 6475 emt6 atcc  (ATCC)
99
ATCC crl 6475 emt6 atcc
(A and B) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing 4T1 mouse triple-negative breast tumor cells. (A) Scheme of treatments. (B) Overall survival data for the four groups of mice with different treatments (n = 8 or 10). (C and D) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing <t>EMT6</t> mouse triple-negative breast tumor cells. (C) Growth of primary tumors. Data are presented as mean ± SEM (n = 8 or 9). (D) Overall survival data for the four groups of mice with different treatments (n = 8 or 9). (E) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing LLC mouse lung cancer cells (n = 8–10). (F) Fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing Pan02 mouse pancreatic cancer cells (n = 7 or 8). (G) NP-G2–044 with anti-PD-1 and anti-CTLA-4 antibodies increase the overall survival of mice bearing PNEC30 mouse prostate cancer cells (n = 8 or 9).
Crl 6475 Emt6 Atcc, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/crl 6475 emt6 atcc/product/ATCC
Average 99 stars, based on 1 article reviews
crl 6475 emt6 atcc - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
mouse mammary carcinoma emt-6  (InVivos Pte Ltd)
90
InVivos Pte Ltd mouse mammary carcinoma emt-6
(A and B) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing 4T1 mouse triple-negative breast tumor cells. (A) Scheme of treatments. (B) Overall survival data for the four groups of mice with different treatments (n = 8 or 10). (C and D) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing <t>EMT6</t> mouse triple-negative breast tumor cells. (C) Growth of primary tumors. Data are presented as mean ± SEM (n = 8 or 9). (D) Overall survival data for the four groups of mice with different treatments (n = 8 or 9). (E) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing LLC mouse lung cancer cells (n = 8–10). (F) Fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing Pan02 mouse pancreatic cancer cells (n = 7 or 8). (G) NP-G2–044 with anti-PD-1 and anti-CTLA-4 antibodies increase the overall survival of mice bearing PNEC30 mouse prostate cancer cells (n = 8 or 9).
Mouse Mammary Carcinoma Emt 6, supplied by InVivos Pte Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse mammary carcinoma emt-6/product/InVivos Pte Ltd
Average 90 stars, based on 1 article reviews
mouse mammary carcinoma emt-6 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
mouse-derived cancer cell line b16f10  (Japan SLC inc)
90
Japan SLC inc mouse-derived cancer cell line b16f10
(A and B) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing 4T1 mouse triple-negative breast tumor cells. (A) Scheme of treatments. (B) Overall survival data for the four groups of mice with different treatments (n = 8 or 10). (C and D) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing <t>EMT6</t> mouse triple-negative breast tumor cells. (C) Growth of primary tumors. Data are presented as mean ± SEM (n = 8 or 9). (D) Overall survival data for the four groups of mice with different treatments (n = 8 or 9). (E) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing LLC mouse lung cancer cells (n = 8–10). (F) Fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing Pan02 mouse pancreatic cancer cells (n = 7 or 8). (G) NP-G2–044 with anti-PD-1 and anti-CTLA-4 antibodies increase the overall survival of mice bearing PNEC30 mouse prostate cancer cells (n = 8 or 9).
Mouse Derived Cancer Cell Line B16f10, supplied by Japan SLC inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse-derived cancer cell line b16f10/product/Japan SLC inc
Average 90 stars, based on 1 article reviews
mouse-derived cancer cell line b16f10 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


(A and B) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing 4T1 mouse triple-negative breast tumor cells. (A) Scheme of treatments. (B) Overall survival data for the four groups of mice with different treatments (n = 8 or 10). (C and D) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing EMT6 mouse triple-negative breast tumor cells. (C) Growth of primary tumors. Data are presented as mean ± SEM (n = 8 or 9). (D) Overall survival data for the four groups of mice with different treatments (n = 8 or 9). (E) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing LLC mouse lung cancer cells (n = 8–10). (F) Fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing Pan02 mouse pancreatic cancer cells (n = 7 or 8). (G) NP-G2–044 with anti-PD-1 and anti-CTLA-4 antibodies increase the overall survival of mice bearing PNEC30 mouse prostate cancer cells (n = 8 or 9).

Journal: Cell reports

Article Title: Fascin inhibitor increases intratumoral dendritic cell activation and anti-cancer immunity

doi: 10.1016/j.celrep.2021.108948

Figure Lengend Snippet: (A and B) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing 4T1 mouse triple-negative breast tumor cells. (A) Scheme of treatments. (B) Overall survival data for the four groups of mice with different treatments (n = 8 or 10). (C and D) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing EMT6 mouse triple-negative breast tumor cells. (C) Growth of primary tumors. Data are presented as mean ± SEM (n = 8 or 9). (D) Overall survival data for the four groups of mice with different treatments (n = 8 or 9). (E) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing LLC mouse lung cancer cells (n = 8–10). (F) Fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing Pan02 mouse pancreatic cancer cells (n = 7 or 8). (G) NP-G2–044 with anti-PD-1 and anti-CTLA-4 antibodies increase the overall survival of mice bearing PNEC30 mouse prostate cancer cells (n = 8 or 9).

Article Snippet: To investigate whether this synergistic effect might be limited to 4T1 tumors, we used EMT6 mouse triple-negative breast tumor cells that are moderately responsive to ICIs (Charles River Laboratories syngeneic mouse models) ( and ).

Techniques:

KEY RESOURCES TABLE

Journal: Cell reports

Article Title: Fascin inhibitor increases intratumoral dendritic cell activation and anti-cancer immunity

doi: 10.1016/j.celrep.2021.108948

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: To investigate whether this synergistic effect might be limited to 4T1 tumors, we used EMT6 mouse triple-negative breast tumor cells that are moderately responsive to ICIs (Charles River Laboratories syngeneic mouse models) ( and ).

Techniques: Control, Recombinant, Plasmid Preparation, shRNA, Membrane